Formulations and methods for lyophilization and lyophilates provided thereby
The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
1. A solid pharmaceutical composition comprising a lyophilized glibenclamide powder substantially free of buffer, including one or more substantially pharmaceutically inert compounds and one or more alkali bases, and being substantially free of other agents that enhance the solubility of glibenclamide, wherein said lyophilized glibenclamide powder comprises less than about 1% w/w buffer and the weight of substantially pharmaceutically inert compounds comprises at least about 10 times the weight of glibenclamide in the solid pharmaceutical composition.
2. The solid pharmaceutical composition of claim 1 , wherein the one or more substantially pharmaceutically inert compounds are independently selected from a sugar and a salt.
3. The solid pharmaceutical composition of claim 1 , wherein the substantially pharmaceutically inert compounds are independently selected from glucose, fructose, mannose, galactose, mannitol, sorbitol, lactose, trehalose, sucrose, sodium chloride, and potassium chloride.
4. The solid pharmaceutical composition of claim 1 , wherein the alkali base is sodium hydroxide or potassium hydroxide.
5. The solid pharmaceutical composition of claim 1 , wherein one of the substantially pharmaceutically inert compounds is mannitol and the alkali base is sodium hydroxide.
6. The solid pharmaceutical composition of any one of claims 1 - 5 , wherein the amount of buffer comprises less than about 0.1% w/w.
7. The solid pharmaceutical composition of claim 1 , wherein the weight of substantially pharmaceutically inert compounds comprises at least about 30 times the weight of glibenclamide in the solid pharmaceutical composition.
8. The solid pharmaceutical composition of claim 1 , wherein said pharmaceutically inert compound is a bulking agent is selected from the group consisting of a mono-saccharide and di-saccharide.
9. The solid pharmaceutical composition of claim 1 , wherein the weight of substantially pharmaceutically inert compounds comprises at least about 100 times the weight of glibenclamide in the solid pharmaceutical composition.